Laura Amanda Boos
Overview
Explore the profile of Laura Amanda Boos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
194
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fendler A, Au L, Shepherd S, Byrne F, Cerrone M, Boos L, et al.
Nat Cancer
. 2022 Feb;
2(12):1321-1337.
PMID: 35121900
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were...
2.
Fendler A, Shepherd S, Au L, Wilkinson K, Wu M, Byrne F, et al.
Nat Cancer
. 2022 Feb;
2(12):1305-1320.
PMID: 35121899
Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune monitoring (CAPTURE) ( NCT03226886 ) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated...
3.
Fendler A, Shepherd S, Au L, Wilkinson K, Wu M, Byrne F, et al.
Nat Cancer
. 2021 Dec;
2:1321-1337.
PMID: 34950880
CAPTURE (NCT03226886) is a prospective cohort study of COVID-19 immunity in patients with cancer. Here we evaluated 585 patients following administration of two doses of BNT162b2 or AZD1222 vaccines, administered...
4.
Fendler A, Au L, Shepherd S, Byrne F, Cerrone M, Boos L, et al.
Res Sq
. 2021 Sep;
PMID: 34580668
Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study (NCT03226886) integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118...
5.
Au L, Boos L, Swerdlow A, Byrne F, Shepherd S, Fendler A, et al.
Cell
. 2020 Sep;
183(1):4-10.
PMID: 32979319
The SARS-CoV-2 pandemic has posed a significant challenge for risk evaluation and mitigation among cancer patients. Susceptibility to and severity of COVID-19 in cancer patients has not been studied in...
6.
Boos L, Leslie I, Larkin J
Expert Opin Investig Drugs
. 2020 May;
29(7):739-753.
PMID: 32401070
: Advanced melanoma historically had a very poor outcome but targeted therapies and immune checkpoint inhibitors (IC) have changed the course of the disease and made durable responses possible. However,...
7.
Leslie I, Boos L, Larkin J, Pickering L
Expert Rev Anticancer Ther
. 2020 Apr;
20(5):343-354.
PMID: 32293937
: The incidence of advanced renal cell carcinoma (RCC) is increasing. Over the last 10 years targeted therapies have led to improved efficacy outcomes for renal carcinoma, including longer survival....
8.
Interlaboratory variability of MIB1 staining in well-differentiated pancreatic neuroendocrine tumors
Blank A, Wehweck L, Marinoni I, Boos L, Bergmann F, Schmitt A, et al.
Virchows Arch
. 2015 Sep;
467(5):543-50.
PMID: 26384025
Neuroendocrine tumors (NET) are routinely graded and staged to judge prognosis. Proliferation index using MIB1 staining has been introduced to assess grading. There are vivid discussions on cutoff definitions, automated...